AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models.
- DOI
- 10.1016/j.xcrm.2026.102762
- Published
- 2026 May 19
- Container
- Cell reports. Medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.xcrm.2026.102762,
title = {AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models.},
author = {Kitakaze K and Ohnishi Y and Tsuji D and Watanabe R and Kamori N and Katakai Y and Shibata H and Yoshizawa S and Ito M and Takino N and Muramatsu SI and Itoh K},
year = {2026},
journal = {Cell reports. Medicine},
doi = {10.1016/j.xcrm.2026.102762},
url = {https://doi.org/10.1016/j.xcrm.2026.102762}
}RIS
TY - JOUR TI - AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models. AU - Kitakaze K AU - Ohnishi Y AU - Tsuji D AU - Watanabe R AU - Kamori N AU - Katakai Y AU - Shibata H AU - Yoshizawa S AU - Ito M AU - Takino N AU - Muramatsu SI AU - Itoh K PY - 2026 JO - Cell reports. Medicine DO - 10.1016/j.xcrm.2026.102762 UR - https://doi.org/10.1016/j.xcrm.2026.102762 ER -
APA
K, K., Y, O., D, T., R, W., N, K., Y, K., H, S., S, Y., M, I., N, T., SI, M., & K, I. (2026). AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models.. Cell reports. Medicine. https://doi.org/10.1016/j.xcrm.2026.102762
Source records
- pubmed · retrieved 2026-09-26T22:13:27.879Z